Comparative overview of dysfunctional behaviors within categories of positive, negative, and cognitive symptoms in the drug induced psychosis model and the schizophrenia model
Animal modelPositive symptomsNegative symptomsCognitive symptomsReference
DIPAmphetamineDisrupted PPI, deficit in latent inhibition, and amphetamine sensitization (1, 3 mg/kg challenge)No effect on social interactionImpaired working memory[2, 9, 12, 14, 83, 84]
ScopolamineDisrupted latent inhibitionSocial recognition deficit in 3-chamber testWorking memory deficit (T-maze spontaneous alteration)[3, 20, 85]
KetamineHyperlocomotionIncreased immobility in forced swim testDeficit in fear conditioning and working memory[4, 35, 86]
PCPHyperlocomotionReduced social interactionAttentional set-shifting deficit (Extra dimensional shift) and disrupted working memory[5, 32, 33, 34, 87]
LSDHyperlocomotionDecreased social behaviorNot reported[6, 42, 45]
Rather, the cognitive function such as increased associate learning was observed
SchizophreniaDISC1Impaired PPI and impaired latent inhibition in mice with mutation L100PDeficit in the forced swim test in mice with mutation Q31LWorking memory deficit in mice with mutation L100P (T-maze)[55, 57]
Neuregulin 1Reduced PPI in mice overexpressing cysteinerich domain variant; hyperlocomotion and reduced PPI in Nrg1 (ΔEGF)+/− mice and typeIII Nrg1 (ΔTM)+/− micSocial recognition deficit in Nrg1 (ΔTM)+/− miceInconsistent results in working memory deficit in Nrg1 (ΔTM)+/− mice[69, 88]
DysbindinHyper responsivity to acute methamphetamineSocial interaction deficitsImpaired working memory[75, 78]

aDIP, drug induced psychosis; PCP, phencyclidine; LSD, lysergic acid diethylamide; DISC1, disrupted-in-schizophrenia-1; PPI, prepulse inhibition; EGF, epidermal growth factor; TM, transmembrane; Nrg, neuregulin.

Exp Neurobiol 2017;26:11~24
© Exp Neurobiol